dzip1l Antibody

What is DZIP1L and why is it important in research?

DZIP1L (DAZ interacting zinc finger protein 1-like) is a centrosomal protein located at the basal body of primary cilia. It has a canonical length of 767 amino acid residues and a mass of 86.8 kDa in humans . As a member of the DZIP C2H2-type zinc-finger protein family, DZIP1L plays a crucial role in primary cilium formation . Its importance in research stems from its association with autosomal recessive polycystic kidney disease (ARPKD), making it a valuable target for studying ciliopathies . DZIP1L is particularly significant because it functions at the transition zone (TZ) of cilia, acting as a gatekeeper for protein composition in cilia and promoting ciliary bud formation .

What are the key structural and functional characteristics of DZIP1L protein?

DZIP1L protein has several important structural and functional characteristics. It contains an N-terminal domain that is critical for proper protein function, as evidenced by mutation studies . The protein is localized to the cytoplasm and specifically to the basal body of primary cilia . Functionally, DZIP1L is required for Hedgehog (Hh) signaling between Smoothened and Sufu, a key developmental pathway . It colocalizes with basal body appendage proteins and Rpgrip1l (a transition zone protein) . DZIP1L interacts with and acts upstream of Cby (an appendage protein) in ciliogenesis and has overlapping functions with Bromi (Tbc1d32) in cilia formation, morphogenesis, and neural tube patterning . Up to two different isoforms of DZIP1L have been reported, and the protein is widely expressed across many tissue types .

How do mutations in DZIP1L affect ciliary function and lead to disease?

Mutations in DZIP1L can significantly disrupt ciliary function through several mechanisms. Loss of DZIP1L results in reduced ciliogenesis and dysmorphic cilia in vivo . Specifically, DZIP1L mutations can arrest ciliogenesis at the stage of ciliary bud formation from the transition zone . Cells with DZIP1L mutations fail to remove the capping protein Cp110 (Ccp110) from the distal end of mother centrioles and fail to recruit Rpgrip1l to the transition zone, preventing proper ciliary development .

In clinical contexts, homozygous DZIP1L sequence variants have been identified in patients with autosomal recessive polycystic kidney disease (ARPKD) . For example, the variant c.216C > G; p.(Cys72Trp) causes mislocalization of the mutant DZIP1L protein, disrupting its normal function . Notably, while patients with PKHD1-associated ARPKD often have liver abnormalities, patients with DZIP1L mutations may not show clinically relevant liver involvement, suggesting a specific pathogenic mechanism .

How does DZIP1L interact with other ciliary proteins in the transition zone assembly?

DZIP1L functions within a complex network of protein interactions at the ciliary transition zone. Research has shown that DZIP1L colocalizes with basal body appendage proteins and directly interacts with Cby, an appendage protein essential for ciliogenesis . This interaction places DZIP1L upstream of Cby in the ciliogenesis pathway, suggesting it may regulate Cby's function or localization .

Additionally, DZIP1L has functional overlap with Bromi (Tbc1d32) in multiple ciliary processes, including ciliogenesis, cilia morphogenesis, and neural tube patterning . This functional redundancy indicates that these proteins may work in parallel or compensatory pathways to ensure proper cilia formation and function.

DZIP1L is also required for the recruitment of Rpgrip1l to the transition zone . Rpgrip1l is a key structural component of the transition zone that helps establish its gatekeeper function. The failure to recruit Rpgrip1l in DZIP1L mutants suggests that DZIP1L plays a crucial role in organizing the molecular architecture of the transition zone, which in turn controls protein entry into and exit from the cilium .

What are the differences between DZIP1L-associated ARPKD and PKHD1-associated ARPKD at the molecular and clinical levels?

At the molecular level, ARPKD is most frequently caused by sequence variants in the PKHD1 gene, which encodes fibrocystin, while DZIP1L mutations represent a rarer cause of the disease . While both proteins are involved in ciliary function, they operate through different mechanisms. DZIP1L is located at the basal body of the primary cilium and is associated with defects in the ciliary trafficking of polycystin-1 and polycystin-2 (the major proteins implicated in autosomal dominant polycystic kidney disease) .

Clinically, a notable difference is that patients with PKHD1-associated ARPKD often have liver abnormalities, whereas patients with DZIP1L mutations may not show clinically relevant liver involvement . This suggests that DZIP1L may have a more kidney-specific role or that its dysfunction affects hepatic cilia differently than PKHD1 mutations. Both conditions share common clinical features including enlarged echogenic kidneys, hypertension, and varying degrees of kidney dysfunction, but the absence of significant liver fibrosis in DZIP1L patients represents an important distinguishing characteristic .

How does the transition zone gatekeeper function of DZIP1L relate to ciliary protein composition and signaling?

DZIP1L plays a critical role in establishing and maintaining the transition zone's gatekeeper function, which controls protein composition within the cilium . This gatekeeping function is essential for proper ciliary signaling, particularly in the Hedgehog (Hh) pathway.

Specifically, DZIP1L is required for Hedgehog signaling between Smoothened and Sufu, placing it at a crucial junction in this developmental pathway . When DZIP1L function is lost, the transition zone's integrity is compromised, leading to dysfunctional protein trafficking into and out of the cilium . This, in turn, disrupts Hedgehog signaling and other ciliary-dependent pathways.

The molecular mechanism involves DZIP1L's role in removing the capping protein Cp110 (Ccp110) from the distal end of mother centrioles, a necessary step for cilia formation . Additionally, DZIP1L facilitates the recruitment of transition zone proteins like Rpgrip1l, which further establish the compartmentalization required for proper ciliary signaling . These functions collectively ensure that the cilium can serve as an effective signaling center for multiple developmental and homeostatic pathways.

What are the optimal immunodetection methods for studying DZIP1L localization and function?

For studying DZIP1L localization and function, several immunodetection methods have proven effective based on the research literature. Immunocytochemistry is reported as the most common application for DZIP1L antibodies, allowing visualization of the protein's subcellular localization . When designing immunocytochemistry experiments, researchers should consider the following protocol elements:

• Cell fixation in formalin followed by permeabilization in 1% Triton X-100 in PBS for 10 minutes at room temperature

• Incubation with mouse polyclonal anti-human DZIP1L protein antibody (1:500 dilution) overnight at 4°C

• Secondary antibody incubation with donkey anti-mouse AlexaFluor568 (1:500 dilution) for 1 hour at room temperature

• DAPI counterstaining (10 μg/ml) for 5 minutes for nuclear visualization

For tissue sections, immunohistochemistry can be performed using:

• Blocking of endogenous peroxidase with H₂O₂ and free aldehyde groups with NH₄Cl in PBS

• Primary antibody incubation overnight at 4°C

• Secondary antibodies conjugated to horseradish peroxidase (HRP)

• Visualization using the DAB+ Substrate Chromogen System

For co-localization studies, double staining techniques can be employed:

• Initial staining with anti-DZIP1L mouse monoclonal antibody and secondary anti-mouse-HRP

• Addition of Cy3-coupled Tyramide Signal Amplification substrate

• Boiling in TEG buffer followed by immunolabeling with a second primary antibody (e.g., anti-AQP2)

• Detection with Alexa Fluor-labeled secondary antibodies

Western blotting, immunofluorescence, and ELISA are also effective methods for DZIP1L detection .

What genetic approaches can be used to study DZIP1L function in model systems?

Several genetic approaches have been successfully employed to study DZIP1L function in model systems:

• Gene Mutation Analysis: Next-generation sequencing approaches, particularly whole-exome sequencing (WES), have proven effective for identifying DZIP1L mutations in patients . Family-based WES approaches can be especially powerful when analyzing consanguineous families with suspected recessive inheritance patterns .

• Site-Directed Mutagenesis: Creating specific mutations in DZIP1L constructs allows for functional analysis of protein variants. For example, introducing the c.216C > G mutation (p.Cys72Trp) can help assess the functional consequences of this pathogenic variant .

• Fusion Protein Construction: N-terminal fusion of EGFP to human DZIP1L using techniques such as Polymerase Incomplete Primer Extension (PIPE) enables visualization of the protein in living cells and assessment of localization patterns of both wild-type and mutant proteins .

• Expression Systems: Plasmid-based expression of DZIP1L constructs in cellular models allows for overexpression studies and rescue experiments in DZIP1L-deficient cells .

• Animal Models: Studies in model organisms with DZIP1L mutations or knockouts can reveal the in vivo consequences of DZIP1L dysfunction, particularly on ciliary formation, neural tube patterning, and kidney development .

All genetic constructs should be verified by Sanger sequencing to confirm the presence of the desired mutations or fusions .

How can researchers design experiments to examine the relationship between DZIP1L and ciliary trafficking?

To examine the relationship between DZIP1L and ciliary trafficking, researchers can design experiments focusing on several key aspects:

• Protein Localization Studies:

  • Compare localization patterns of wild-type and mutant DZIP1L tagged with fluorescent proteins

  • Perform co-localization studies with known ciliary markers and transition zone proteins like Rpgrip1l

  • Use super-resolution microscopy to precisely map DZIP1L's position relative to other basal body and transition zone components

• Protein-Protein Interaction Analysis:

  • Conduct co-immunoprecipitation experiments to identify DZIP1L's binding partners in the ciliary trafficking machinery

  • Use proximity ligation assays to confirm interactions in intact cells

  • Employ yeast two-hybrid or BioID approaches to discover novel interactors

• Functional Trafficking Assays:

  • Track the movement of fluorescently labeled ciliary proteins in cells with normal or disrupted DZIP1L function

  • Monitor the removal of Cp110 capping protein from mother centrioles in DZIP1L-deficient cells

  • Assess the recruitment of transition zone proteins like Rpgrip1l in the presence or absence of functional DZIP1L

• Signaling Pathway Analysis:

  • Measure Hedgehog pathway activity using reporter assays in cells with varying levels of DZIP1L expression

  • Examine the localization of Smoothened and Sufu in response to Hedgehog stimulation in DZIP1L-deficient cells

  • Investigate the trafficking of polycystin-1 and polycystin-2 in models of DZIP1L dysfunction

• Rescue Experiments:

  • Reintroduce wild-type DZIP1L in knockout cells to assess restoration of normal ciliary trafficking

  • Test domain-specific DZIP1L constructs to identify regions essential for trafficking functions

How should researchers interpret immunostaining patterns of DZIP1L in normal versus disease tissues?

When interpreting immunostaining patterns of DZIP1L in normal versus disease tissues, researchers should consider several key factors:

• Normal Localization Patterns:

  • In normal tissues, DZIP1L typically localizes to the basal body of primary cilia

  • DZIP1L may also show cytoplasmic distribution, consistent with its reported subcellular localization

  • Look for co-localization with basal body appendage proteins and transition zone proteins like Rpgrip1l

• Disease Tissue Patterns:

  • In tissues with DZIP1L mutations, expect mislocalization of the protein, particularly with mutations affecting the N-terminal domain like p.Cys72Trp

  • Look for reduced or absent DZIP1L staining at the basal body

  • Assess correlation between DZIP1L mislocalization and ciliary abnormalities, such as reduced cilia number or dysmorphic cilia

• Comparative Analysis:

  • Compare staining intensity and distribution between control and disease samples

  • Quantify the percentage of cells showing proper DZIP1L localization

  • Measure co-localization coefficients with ciliary markers in normal versus disease states

• Tissue-Specific Considerations:

  • DZIP1L is widely expressed across many tissue types , but may show tissue-specific localization patterns

  • In kidney tissue, correlate DZIP1L staining patterns with cystic changes in ARPKD

  • Compare kidney versus liver staining in patients with DZIP1L mutations versus PKHD1 mutations, noting that DZIP1L patients may lack significant liver involvement

• Technical Considerations:

  • Validate antibody specificity using positive and negative controls

  • Consider fixation artifacts that might affect apparent localization

  • Use multiple antibodies targeting different epitopes when possible to confirm staining patterns

What bioinformatic approaches can help predict the functional impact of novel DZIP1L variants?

Several bioinformatic approaches can help predict the functional impact of novel DZIP1L variants:

• Evolutionary Conservation Analysis:

  • Assess nucleotide and amino acid conservation across species

  • The cysteine residues at positions 65 and 72 have been found to be highly conserved in vertebrates (chimp, macaque, rat, mouse, rabbit, dog, cat, cow, and frog), suggesting functional importance

• Prediction Algorithms:

  • Apply multiple prediction tools including MutationTaster, PolyPhen-2, and SIFT

  • Consider variants predicted as damaging by multiple algorithms to be higher priority

  • Use CADD (Combined Annotation Dependent Depletion) scores to rank variant pathogenicity; scores above 20 often indicate deleterious variants

• Structural Modeling:

  • Generate protein structure models to assess how mutations might affect protein folding and function

  • Focus on critical domains like the N-terminal region, which has been shown to be important for proper DZIP1L function

• Population Frequency Analysis:

  • Check variant frequencies in population databases such as the Exome Variant Server, ExAC database, and gnomAD database

  • Rare or absent variants are more likely to be pathogenic

  • Consider population-specific frequencies when interpreting variants

• Homozygosity Mapping:

  • In consanguineous families, identify regions of homozygosity (ROH) that might harbor recessive disease-causing variants

  • Compare ROH patterns between affected individuals to narrow down candidate regions

• Haplotype Analysis:

  • Compare polymorphisms in DZIP1L to determine if affected individuals from different families share the same haplotype, suggesting a common ancestor

How can researchers distinguish between primary effects of DZIP1L dysfunction and secondary consequences in ciliopathy models?

Distinguishing between primary effects of DZIP1L dysfunction and secondary consequences in ciliopathy models requires careful experimental design and analysis:

• Temporal Studies:

  • Conduct time-course experiments to identify the earliest detectable changes following DZIP1L disruption

  • Primary effects typically occur earlier and directly involve ciliary formation or function

  • Secondary effects develop later as physiological consequences of ciliary dysfunction

• Molecular Hierarchy Analysis:

  • Use rescue experiments with wild-type DZIP1L to determine which phenotypes can be directly reversed

  • Establish the sequence of molecular events following DZIP1L disruption

  • Map DZIP1L in known ciliary pathways to determine its position relative to other proteins (e.g., DZIP1L acts upstream of Cby in ciliogenesis)

• Domain-Specific Mutations:

  • Create targeted mutations affecting specific domains of DZIP1L

  • Compare phenotypes across different domain mutations to identify domain-specific functions

  • Correlate specific molecular defects with particular phenotypic outcomes

• Comparative Models:

  • Compare phenotypes between DZIP1L models and other ciliopathy models (e.g., PKHD1 mutants)

  • Shared phenotypes across multiple ciliopathy models likely represent common downstream effects

  • Unique phenotypes in DZIP1L models may indicate specific functions

• Pathway-Specific Readouts:

  • Measure specific ciliary-dependent pathway activities (e.g., Hedgehog signaling)

  • Determine whether pathway disruptions occur at the level where DZIP1L is known to function (between Smoothened and Sufu in Hedgehog signaling)

  • Use small molecule modulators of specific pathways to determine which processes can be rescued independent of DZIP1L

• Cellular Phenotype Analysis:

  • Distinguish between defects in ciliary formation (e.g., failure to remove Cp110 or recruit Rpgrip1l) versus defects in ciliary function

  • Quantify primary cellular phenotypes such as cilia number, length, and morphology

  • Correlate cellular phenotypes with tissue-level and organismal phenotypes

What are the key unresolved questions about DZIP1L function in ciliary biology?

Despite significant advances in understanding DZIP1L, several key questions remain unresolved in ciliary biology. Current research has established DZIP1L as a basal body protein involved in ciliary bud formation and transition zone integrity , but the precise molecular mechanisms by which it performs these functions are not fully elucidated.

The complete protein interaction network of DZIP1L remains to be mapped, particularly how it interfaces with the diverse protein complexes at the ciliary base. While we know DZIP1L interacts with Cby and affects the localization of Rpgrip1l , its interactions with other transition zone and basal body components require further investigation.

Additionally, the tissue-specific aspects of DZIP1L function remain poorly understood. The observation that DZIP1L mutations may cause kidney disease without significant liver involvement (unlike PKHD1 mutations) suggests tissue-specific roles or redundancies that have not been fully characterized.

The regulatory mechanisms controlling DZIP1L expression, localization, and function also represent a significant knowledge gap. Understanding how DZIP1L is itself regulated during development and disease could provide insights into potential therapeutic approaches for DZIP1L-related ciliopathies.

Finally, while DZIP1L mutations have been associated with autosomal recessive polycystic kidney disease , the potential involvement of DZIP1L in other ciliopathies or developmental disorders warrants further investigation. Expanding the phenotypic spectrum associated with DZIP1L dysfunction could reveal new roles for this protein in human disease.

How might therapeutic approaches targeting DZIP1L be developed for ciliopathies?

Developing therapeutic approaches targeting DZIP1L for ciliopathies will require innovative strategies addressing the unique challenges of ciliary diseases. Several potential approaches could be considered:

• Gene Therapy:

  • Delivery of functional DZIP1L genes to affected tissues using viral vectors

  • CRISPR-Cas9 gene editing to correct specific DZIP1L mutations in patient cells

  • These approaches would be most applicable to loss-of-function mutations in DZIP1L

• Small Molecule Modulators:

  • Development of compounds that could stabilize mutant DZIP1L protein or enhance its residual function

  • Identification of molecules that could bypass DZIP1L dysfunction by directly targeting downstream effectors

  • High-throughput screening of compound libraries using cellular models of DZIP1L dysfunction

• Protein Replacement or Stabilization:

  • Design of protein delivery systems to introduce functional DZIP1L protein into affected cells

  • Development of proteostasis modulators that might stabilize misfolded DZIP1L variants like p.Cys72Trp

• Pathway-Based Approaches:

  • Since DZIP1L functions in the Hedgehog signaling pathway , modulators of this pathway might compensate for DZIP1L dysfunction

  • Targeting the removal of Cp110 or the recruitment of Rpgrip1l by alternative mechanisms could potentially bypass DZIP1L requirements

• Personalized Medicine Approaches:

  • Development of mutation-specific therapies based on the particular DZIP1L variants in individual patients

  • Utilization of patient-derived cells for drug screening and therapy development